Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients with diabetes: results of the POWER survey

Robert J Petrella1 Departments of Family Medicine, Medicine (Cardiology) and Kinesiology, University of Western Ontario, London, ON, Canada;2 Aging, Rehabilitation and Geriatric Care Research Centre, Lawson Health Research Institute, London, ON, Canada;3 Department of Family Medicine and School of Health Studies, University of Western Ontario, London, ON, CanadaCorrespondence[email protected]

Dawn P Gill2 Aging, Rehabilitation and Geriatric Care Research Centre, Lawson Health Research Institute, London, ON, Canada;3 Department of Family Medicine and School of Health Studies, University of Western Ontario, London, ON, Canada

Jean-Pascal Berrou4 Abbott Products Operations AG, Allschwil, Switzerland

Pages 173-180 | Published online: 24 Mar 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

LeeDSChiuMManuelDGTrends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factorsCMAJ20091813–4E55 E6619620271
PubMed Web of Science ®Google Scholar
CampbellNRLeiterLALarochellePHypertension in diabetes: a call to actionCan J Cardiol2009255299 30219417860
PubMed Web of Science ®Google Scholar
LeeDGoodmanSGFoxKAPrognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertensionAm Heart J20131664716 72224093852
PubMed Web of Science ®Google Scholar
DaskalopoulouSSKhanNAQuinnRRThe 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapyCan J Cardiol2012283270 28722595447
PubMed Web of Science ®Google Scholar
GroverSAHemmelgarnBJosephLMilotATremblayGThe role of global risk assessment in hypertension therapyCan J Cardiol2006227606 61316755316
PubMed Web of Science ®Google Scholar
PetrellaRJTremblayGDe BackerGGillDPPOWER survey Study GroupEffect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER surveyVasc Health Risk Manag20141063 7424493928
PubMedGoogle Scholar
De BackerGPetrellaRJGoudevARRadaidehGARynkiewiczAPathakADesign and methodology of POWER, an open-label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertensionFundam Clin Pharmacol2013272210 21522049922
PubMed Web of Science ®Google Scholar
WilsonPWD’AgostinoRBLevyDBelangerAMSilbershatzHKannelWBPrediction of coronary heart disease using risk factor categoriesCirculation199897181837 18479603539
PubMed Web of Science ®Google Scholar
LeenenFHDumaisJMcInnisNHResults of the Ontario survey on the prevalence and control of hypertensionCMAJ2008178111441 144918490640
PubMed Web of Science ®Google Scholar
AndalibAAkhtariSRigalRDeterminants of masked hypertension in hypertensive patients treated in a primary care settingIntern Med J2012423260 26621118414
PubMed Web of Science ®Google Scholar
LiddyCSinghJHoggWQuality of cardiovascular disease care in Ontario, Canada: missed opportunities for prevention – a cross sectional studyBMC Cardiovasc Disord2012127422970753
PubMed Web of Science ®Google Scholar
BhanVYanRTLeiterLARelation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatientsAm J Cardiol201010691270 127621029823
PubMed Web of Science ®Google Scholar
Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects)LuYHajifathalianKMetabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participantsLancet20143839921970 98324269108
PubMed Web of Science ®Google Scholar
Hypertension CanadaThe 2012 Canadian Hypertension Education Program Recommendations (Full Version)Markham (ON)Canadian Hypertension Education Program2012 Available from: http://www.hypertension.ca/images/2012_CHEPRecsFullVersion_EN_HCP1000.pdfAccessed September 11, 2014
Google Scholar
AokiJUchinoKTreatment of risk factors to prevent strokeNeurotherapeutics201183463 47421713592
PubMed Web of Science ®Google Scholar
DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995 100311937178
PubMed Web of Science ®Google Scholar
SchraderJLüdersSKulschewskiAMorbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)Stroke20053661218 122615879332
PubMed Web of Science ®Google Scholar
Blood Pressure Lowering Treatment Trialists’ CollaborationTurnbullFNealBBlood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin systemJ Hypertens2007255951 95817414657
PubMed Web of Science ®Google Scholar
PohlMABlumenthalSCordonnierDJIndependent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitationsJ Am Soc Nephrol200516103027 303716120823
PubMed Web of Science ®Google Scholar
HellemonsMEPerssonFBakkerSJInitial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trialDiabetes Care20113492078 208321788629
PubMed Web of Science ®Google Scholar
BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med200134512861 86911565518
PubMed Web of Science ®Google Scholar
VibertiGWheeldonNMMicroAlbuminuria Reduction With VALsartan (MARVAL) Study InvestigatorsMicroalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effectCirculation20021066672 67812163426
PubMed Web of Science ®Google Scholar
GrundySMPrimary prevention of coronary heart disease: integrating risk assessment with interventionCirculation19991009988 99810468531
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients with diabetes: results of the POWER survey

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients with diabetes: results of the POWER survey

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date